About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight Report to 2030: U.S. Leads in Peptide Vaccine Development with Over 20 Active Projects - ResearchAndMarkets.com

The "Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Cancer remains among the most common causes of death globally, and current therapies like chemotherapy and radiation are frequently associated with serious side effects and inconsistent response rates. In such an instance, peptide based cancer vaccines could offer a viable option for targeted immune mediated cancer destruction with less toxicity. Such vaccines utilize tumor specific or neoantigenic peptides to generate extremely specific T-cell responses with the precision of immunotherapy without the intricacy of cell or viral vector platforms.

This report is aimed at filling an expanding market need by delivering stakeholders, including biotech firms, investors, healthcare planners, and regulators, with practical insights into the dynamic cancer peptide vaccine market. With a number of candidates undergoing clinical trials and nearing commercialization, insight into the current situation and future direction is necessary for intelligent decision making.

Clinical Trials Insight Included in the Report

The report delivers in-depth information from more than 50 ongoing and completed clinical trials from all over the globe. It provides a breakdown of the pipeline by trial phase, cancer type, therapeutic target, and combination regimen, as well as sponsors, collaborators, technology licensors, and geographic regions. Interestingly, there is heightened interest in multivalent vaccines acting on several epitopes as well as peptide vaccines under investigation with checkpoint inhibitors.

Among the late stage clinical contenders, SELLAS Life Sciences' Galinpepimut-S is in a Phase III trial for AML and has also been active in mesothelioma. Other ongoing trials involve peptide vaccines in NSCLC, prostate cancer, triple-negative breast cancer, and glioblastoma. The trials cover a number of geographies, such as the US, EU, Japan, China, and South Korea, highlighting the international appeal of peptide vaccine platforms.

Leading Companies Engaged in R&D of Peptide Cancer Vaccine

There are numerous biotechnology companies as well as pharmaceutical firms that are developing peptide based immunotherapy pipelines. Some of the key players are Scancell Holdings, SELLAS Life Sciences, ISA Pharmaceuticals, Imugene, and BrightPath Biotherapeutics. They are all working on both monovalent and polyvalent vaccine strategies.

Every firm has its own distinct approach; some aim at common tumor antigens, whereas others design customized neoantigen vaccines based on next-generation sequencing results. Then there are participants such as OncoTherapy Science and VAXON Biotech that are creating cancer-specific pipelines, in general, aimed at antigens such as WT1, MAGE-A3, or survivin.

Technology Platforms, Collaborations & Agreements

The peptide cancer vaccine market is more and more influenced by cutting-edge technology platforms and strategic partnerships. Exclusive platforms like Moditope (Scancell) and T-win (IO Biotech) are the main differentiators that improve immunogenicity and delivery efficacy. Such platforms allow improved epitope presentation, activation of immune cells, and minimizing the risk of immune escape.

Collaborations are now essential to the advancement of pipelines. Numerous companies are entering co-development deals with CDMOs, academic institutions, or bigger pharma partners. For instance, SELLAS has collaborated with Memorial Sloan Kettering for its GPS vaccine, and various companies are collaborating with regional manufacturing partners in Europe and Asia for ramping up GMP production. Licensing deals are also increasing, allowing the exchange of peptide libraries and immunoinformatics tools among partners.

Report Indicating Future Direction of Peptide Cancer Vaccine Segment

The report suggests a very promising but competitive future for cancer peptide vaccines. Although Riavax is currently the sole peptide vaccine that has obtained market approval in South Korea, which was subsequently withdrawn, it demonstrated the validity of the concept. The science has developed considerably since, however, with enhanced antigen discovery, more efficient stratification of patients, and a move towards combination forms of therapy.

The destiny of this space will most probably be controlled by multiepitope vaccines and neoantigen personalization enabled by AI and big data analysis. Commercial interest is likely to increase in unmet need indications like glioblastoma, pancreatic cancer, and refractory NSCLC. With regulatory agencies offering clearer guidelines for immunotherapy approvals and integration of real-world data, some late-stage peptide vaccines may receive approvals in the next 3-5 years.

This report is a must read for stakeholders looking to ride the increasing tide in this space, providing data-driven insights on innovation trends, trial updates, collaborations, and commercialization channels in the landscape of peptide cancer vaccines.

Report Findings & Highlights:

  • Global & Regional Market Trends Insight
  • Peptide Cancer Vaccine Classification by Source, Length & Epitope Specificity
  • Peptide Cancer Vaccines in Clinical Trials: > 50 Vaccines
  • US Dominating Peptide Cancer Vaccines Development Landscape: > 20 Vaccines
  • Global Peptide Cancer Vaccine Clinical Trials Insight by Company, Country, Phase & Indication
  • Insight on Peptide Cancer Vaccine Development Technology Platforms by Companies
  • Completive Landscape

Key Topics Covered:

1. Introduction to Peptide Cancer Vaccines

1.1 Overview & Historical Context

1.2 Peptide Based Immunotherapy in Oncology

2. Need for Peptide Cancer Vaccines

2.1 Why Peptides are More Desirable in Cancer Immunotherapy

2.2 Peptide Vaccines vs. Traditional Cancer Vaccines

2.3 Gaps Addressed by Peptide Vaccines

3. Peptide Cancer Vaccines Mechanism of Action

4. Classification of Peptide Cancer Vaccines

4.1 Based on Source of Peptides

4.2 Based on Peptide Length

4.3 Based on Epitope Specificity

5. Peptide Cancer Vaccines Development & Clinical Trends by Indication

5.1 Brain Cancer

5.2 Breast Cancer

5.3 Lung Cancer

5.4 Skin Cancers

5.5 Gastrointestinal Cancers

5.6 Gynecologic Cancers

6. Global Peptide Cancer Vaccine Market Overview

6.1 Current Market Landscape

6.2 Future Outlook & Innovation Opportunities

7. Global Peptide Cancer Vaccine Market Development Trends by Region

7.1 US

7.2 Europe

7.3 China

7.4 Japan

7.5 South Korea

8. Global Peptide Cancer Vaccine Pipeline Overview

8.1 By Country

8.2 By Company

8.3 By Indication

8.4 By Phase

9. Global Peptide Cancer Vaccine Clinical Trials Insight by Company, Country, Phase & Indication

9.1 Preclinical

9.2 Phase-I

9.3 Phase-I/II

9.4 Phase-II

9.5 Phase-III

10. Global Peptide Cancer Vaccine Market Dynamics

10.1 Key Drivers & Opportunities

10.2 Market Challenges & Limitations

11. Technology Platforms for Peptide Cancer Vaccine Development by Companies

12. Competitive Landscape

  • 3D Medicines
  • BrightPath Biotherapeutics
  • Cecava
  • Circio Holding
  • Dx&Vx
  • Elicio
  • Evaxion
  • GemVax & KAEL
  • IO Biotech
  • ISA Pharmaceuticals
  • Nouscom
  • Nykode Therapeutics
  • OncoTherapy Science
  • OSE Immunotherapeutics
  • Scancell
  • SELLAS Life Sciences
  • Seqker Biosciences
  • Shionogi
  • Vaxon Biotech
  • Zelluna

For more information about this report visit https://www.researchandmarkets.com/r/iuyu1y

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.